Mass population screening for colorectal cancer is currently being evaluated concurrently in several countries, by means of randomised controlled trials (Miller et al., 1991) . The largest of these in terms of subject recruitment is that being undertaken at the University Hospital, Nottingham, UK. The Nottingham trial was initiated in 1981 and has now attained its recruitment target of 155,000 subjects, randomised into study and control groups of equal size.
Patients with advanced colorectal cancer typically present with symptoms such as acute pain and poor bowel functioning, owing to constriction caused by the growth of the tumour on and into the bowel wall. At the early, presymptomatic phase, however, tumours tend not to obstruct noticeably, although they are likely to bleed and to deposit minute quantitites of blood in the stool. Such deposits cannot be observed visually but they can be detected chemically. The study group has been offered the self-administered HaemoccultTM faecal occult blood (FOB) test every 2 years. Pea-size stool samples are taken on three successive days, smeared onto guaiac-impregnated paper, and the completed test is returned to the processing laboratory. The addition of a reagent produces a characteristic colour change if occult blood is present in the stool sample, such as reaction being suggestive of a bleeding and possibly malignant neoplasm in the colon or rectum. Subjects with positive test results proceed to endoscopic or radiological investigation. The subject compliance rate to 1989 averaged 57.8% for the initial test and 77.0% for the first re-test. Patients with screen-detected and symptomatic-presenting cancers in both groups have been followed up fully (Hardcastle et al., 1983; . The trial will involve five complete screening rounds for all subjects and is thus expected to continue into the late-1990s.
Economic appraisal forms an important component in the evaluation of any cancer screening programme. The initial concern of the economic appraisal of the Nottingham trial was the examination of the cost implications of differing screening protocols, i.e. the costs of detecting colorectal cancer by screening (Walker et al., 1991a; Whynes et al., 1992 (Wagner et al., 1990 (Pollard et al., 1989) .
To July 1991, 360 trial patients met the 3-year follow-up criterion. All were treated by surgical interventions alone. The hospital notes of these patients provided the primary data for the costing study, yielding information on types of diagnostic investigation performed, lengths of inpatient stay (including intensive care), duration and types of operations, radiology, pathology and ECG requests. The majority of these categories of data may be directly translated into costs using the University Hospital's financial returns. Exceptions study and the control group cases. In consequence, no bias should be imparted as a result of this omission.
The University Hospital is a major teaching and research centre, and hence procedures related to research were omitted from the cost estimates wherever possible. For example, a comparative trial of pre-operative methods of imaging rectal cancer was in progress during part of the study period: all resources used as a result have been excluded. Only treatment costs related directly to colorectal cancer were included in the 3-year post-diagnosis follow-up period.
Results
Study group cancers may be divided into three categories: (i) those detected in patients as a result of their acceptance of the offer of FOB screening (screen-detected cases), (ii) those presenting in patients either who did not respond or who refused the offer of screening (no-response cases), (iii) those presenting between screening rounds in patients who had previously recorded a negative FOB test (interval cases). Table I presents the numbers of cancers for the control group and for each of the study group categories. As may be inferred, the cancer yield was 37% higher in the study group compared with the control group. The table also displays the mean treatment costs for patients, divided into five time periods:
(i) costs relating to the initial investigation and diagnosis; (ii) pre-operative costs, incurred between admission to hospital and the initial, main operation;
(iii) the costs of the main treatment or operation, up to the time of first discharge; (iv) costs incurred as a result of any short-term subsequent re-admission, for the purpose of completing the main operation or dealing with complications arising therefrom; (v) other cancer-related treatment costs incurred between discharge from re-admission and 3 years post-diagnosis (or death). Figure 1 portrays total costs as frequency distributions.
Statistical comparisions of means between the control group and the three study sub-groups for each cost category indicate no significant differences (t-test at 5%), with three exceptions; first, the difference between investigation costs for screen-detected cancers and controls (£47, confidence intervals £25 to £69), second, the difference between main treatment cost for screen-detected and no-response cases (£610, confidence intervals £1 11 to £1,109), third, the difference between total cost for screen-detected and no-response cases (£959, confidence intervals £249 to £1,669).
From the data on individual patients, those with low treatment costs were identified ('low' defined as costs less than or equal to one standard deviation below the mean for the relevant cost distribution). Within the control group, there were 14 such cases. Of these, four patients underwent polypectomy and three survived to the end of the 3-year follow-up period. The remaining 10 patients died, seven before or during the first admission and the remaining three within 6 months of diagnosis. For the no-response group seven of the 12 died at or before the time of admission, and a £3,277 (s.d. 2,737) . The difference between these means is insignificant (t-test, P>0.1).
Discussion
On the basis of the Nottingham evidence presented above, we find no support for the hypotheses that the cost of treatment for early-stage cancer is less than the cost of treating the late-stage counterpart over a 3 year period.
The clear discrepancy between our finding and that of the cited US studies requires some words of explanation, and there exist several possibilities in this respect. First, in some instances, US results have been based on exceptionally small samples, as low as 13 cancers in total in one case (Allison & Feldman, 1985) . Those findings, accordingly, may be prone to small sample bias. Second, in none of the cited US cases had recruitment occurred via a randomised controlled trial, suggesting a prior selection of subjects according to some other criterion (for example, membership of a specific insurance plan). This might represent a source of selection bias. Perhaps most important of all, the costs used in the US evaluations are not, technically speaking, costs at all; they are charges or prices levied by (mostly) private hospitals and accepted as valid by the financial institutions responsible for payment (Finkler, 1982) . Evidence suggests that the intensity and duration of hospital treatment for colorectal cancer in the USA (which is the principal determinant of total costs) varies with the nature of the patient's health insurance package (Heine & Rothenberger, 1991) . Different packages thus permit hospitals to levy different charges on their customers. As charges result from bargaining between hospitals and insurers, they bear no clear relationship to actual resource usage during treatment. It is therefore quite probable that the US price differential between early-and late-stage cancer treatment arises as much from a negotiated agreement between care suppliers and purchasers as it does from any differential use of inputs.
By far the largest cost component over the 3 year period is the main treatment episode, 65 and 69% in the study and control groups, respectively. Although polypectomy offers the principal hope for economies in treatment costs resulting from screening, in only 15 cases did simple polypectomy represent the sole treatment episode (ten screen-detected, one no-response, four controls). All of these cases were stage A cancers, with a mean treatment cost of £257 (s.d. 142). However, the fact that a cancer is at a very early stage or confined within a polyp does not guarantee that treatment can be effected successfully by polypectomy alone (Langer et al., 1984; Morson et al., 1984; Russell et al., 1990) , nor does it preclude the possibility of recurrence at a later stage (Lotfi et al., 1986) . Indeed, the remaining stage A cancers in the combined sample (80%) all required resections at a higher cost, although at a lower cost than that necessitated by the treatment of stages B and C cancers. In six cases, readmission occurred, after-care was required in nine cases, whilst seven patients experienced both re-admission and after-care.
It is evident that any treatment cost advantage which might have been anticipated as a result of screening has been substantially eroded by the high costs incurred by the noresponse group. The proportion of costs per case in excess of £5,000 is considerably higher for this group than for both control and screen-detected cases (21.0%, compared with 11.2 and 10.4% respectively). The reasons for this cost difference are, at present, unclear. From the results, it is possible that cancers in no-response cases are more difficult to treat or that no-response patients are worse affected by both disease and treatment.
Conclusions
Accepting the Nottingham finding, it accordingly follows that substantial economies in treatment costs during the 3 years following initial diagnosis should not be anticipated following the implementation of a colorectal cancer screening programme. This is because detection at early-, as opposed to late-, stage appears to make no significant difference to hospital treatment costs. Indeed, if one were to argue that a screening programme would detect a cancer at the asymptomatic early stage some years in advance of detecting it symptomatically at the late stage, then the discounted treatment 967 cost would actually be higher under the screening scenario. Sizeable treatment cost economies as a result of screening would only become evident if the staging distribution were to be 'rolled forward' such that the proportion of specifically stage A cancers came to dominate the total. Such a situation could only be envisaged under the assumptions that the programme were to be screening for incident cancers only, and had high sensitivity and compliance rates.
This result, however, should not be taken to pre-judge the cost-effectiveness, or otherwise, of such a programme. From the evidence presented, it is reasonable to conclude that the principal explanation of low treatment cost in the screendetected cases is cheap and successful initial intervention. By contrast, the explanation for low cost in other categories is early patient death, obviating the need for treatment. There are already evidence from other sources that expected survival gains are strongly correlated with cancer stage at diagnosis (Jatzko et al., 1992) , and it is expected that the Nottingham trial will also demonstrate such gains when its survival results are eventually published. The implication is that, whilst treatment costs may presently show no differences under a screening vs a non-screening scenario, outcome benefits are likely to be superior under the former, given the difference in the staging distribution. Although important, treatments costs are only one element in the cost-effectiveness equation which remains to be fully identified.
